Efficacy predictors of a second tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis.

Age, BMI, insurance provider, gender, anti-CCP status, concomitant DMARD therapy (not included in table), and disease duration prior to initiation of the first TNFi did not reach statistical significance when analyzed for impact on transient efficacy versus no efficacy.

also in 111,027 other papers

While our data suggests a possible trend toward greater efficacy of the weight-based infliximab as a 2nd TNFi in those with higher BMIs, our data set is under-powered to draw any definite conclusions.

also in 1,410 other papers